Good morning, everyone, and welcome to Sleep Cycle AB's second quarter earnings call. I'm Erik Jivmark. I'm the CEO, and I'm joined by Elisabeth Hedman, our CFO and Head of Investor Relations. So Q2 was a demanding quarter for the consumer business, but it was also a quarter where the strategic shift we have been building towards became increasingly tangible. So today, I want to spend most of my time on that shift. What is changing in our market, how we are broadening the business beyond the app and the progress we're seeing across the three growth pillars. But first, our mission. It has not changed. We want to improve global health by helping people take control of their sleep. What is changing, though, is how we scale that mission. We're moving beyond app stores. So Sleep Cycle starts from a position that is difficult to replicate. We have analyzed more than 4 billion nights of sleep. We have reached more than 82 million installs, and we have built a large active user base over more than a decade. And importantly, this was built largely through organic growth and also with a very efficient operating model. So when we talk about moving beyond the app, we're not starting a new business from scratch. We are leveraging our technology, data distribution, and sleep expertise that already exists. And we apply that in more ways, and thereby, we're taking control of our own destiny.
So this chart explains where we are in the journey from 2021 to 2025. We built a highly profitable consumer business. Revenue grew, margins expanded, and B2B gradually became a larger part of the mix. 2026 is different. We are deliberately investing more heavily in new growth areas while the consumer business is under pressure. But we're funding that transformation from the business we have already built, and the objective is clear: from 2027 and onward, we want several growth engines rather than relying almost entirely on one consumer subscription product. That is the transition that we're making. And the reason why we can do that is because the underlying opportunity around sleep is broadening. Sleep is increasingly connected to health, performance, recovery, and even longevity, and therefore the way consumers experience sleep technology is also changing. It's moving into all the different spaces such as wearables, digital health, even pharma, smart home products, and broader health platforms. And those environments increasingly value exactly the type of technology we have built: passive sensing, continuous insights, and software that can operate in the background. So the important point is that the sleep opportunity is increasingly larger than the standalone sleep app category, where we have historically been operating. That also changes the market that we can address. Historically, we operated primarily in a sleep app market around 1.7 billion SEK. By applying the same underlying technology to sleep apnea and tech licensing. Our estimated addressable market expands to around 47 billion SEK annually. That is the structural change.
So the same core technology, more use cases, more distribution channels, and much larger markets.
So this brings us to the three pillars of the strategy. First, we have the Sleep Cycle app. It remains our consumer engine. It is our largest source of revenue and an important distribution platform. This is where the majority of our staff is focusing their time. Secondly, we have sleep apnea, where we want to apply our technology to a significantly larger medical need and a much larger market. And thirdly, we have tech licensing, where partners can embed the Sleep Cycle technology directly into their own products and ecosystems. What connects all these is the same underlying technology platform. And that is very important because we are not building three unrelated businesses. What we're doing is we're creating multiple routes to market from the capabilities we already have.
I want to zoom in a little bit on each of these pillars, starting with the app. There is no other way to put it than the consumer business remains under pressure, particularly at the top of the funnel. Acquisition is the main challenge, but underneath the headline, there are several encouraging signals. We continue to gain download shares within the Meditation and Sleep Tracker segment on iOS. Pricing has held up. We have an FX-adjusted ARPU of 286. We also see that engagement is improving. We have a threefold increase in sleep aid usage. Let me mention one thing, we are starting to build distribution outside the traditional App Store funnel. So web to app is still small, but conversion and monetization are moving materially in the right direction. So the diagnosis is very straightforward. We need to rebuild acquisition. But the underlying product economics and also the engagement give us something to build from. Turning to sleep apnea. Before we go into the details of the program, I think it's worth keeping the opportunity in mind. So sleep apnea is a very large and highly undiagnosed condition. Traditional diagnostic pathways are expensive and difficult to scale. Our ambition is to make risk detection significantly more accessible through a software-only approach. 150,000 people who have already signed up and registered interest give us an indication that there is a real consumer demand ahead of launch.
And the same goes for B2B, where we have a lot of interesting conversations right now with potential partners.
But let's talk a little bit about the clinical validation study. So the original study itself has been executed essentially as planned. The challenge is that fewer participants than expected have turned out to have moderate to severe OSA. Importantly, participants cannot be recruited based on a previously known sleep apnea diagnosis. So we only know the clinical mix after the study nights have been completed. We do not know it beforehand. As a result, we need to find more people that have moderate to severe OSA. Therefore, additional enrollment is required to secure the statistical basis for the regulatory approval, which will require a materially larger investment and shift the timeline. The newly appointed board is currently preparing the decision on the scope of the extension. Our ambition to achieve regulatory approval in the US remains unchanged. We will, of course, communicate an updated timeline once the decision has been taken. It's also important to separate the need for additional enrollment from the broader regulatory program. We have achieved a number of significant milestones in this quarter. We have external specialists who have been validating the regulatory approach that we are taking. The quality system is being established against the relevant standards. The documentation has passed an external audit and the design phase is done. So the work is now about completing the required clinical evidence that we need.
The dates beyond Q2. You should see those as preliminary. And it depends, of course, on the board's decision and the pace of recruitment, but our ambition remains US regulatory approval during 2027. Finally, tech licensing. This is where we are increasingly moving from platform development to commercial adaptation. We now have a broad set of partner-ready capabilities, and these capabilities can be embedded across a wide range of partner ecosystems. And I think, more importantly, we have commercial proof after the quarter.
Ultrahuman converted their pilot into a commercial SDK license. We started an SDK pilot with Ant Group. This gives us an entry into the Chinese market, and our global IoT agreement starts to contribute revenue now in Q3. We have also completed the UKHSA research and the collaboration we had there around cough data. So this is increasingly becoming a real commercial business, not a strategic pipeline.
And with that, I'll hand over to Elisabeth to take you through the financial performance.